Enterprise Therapeutics Closes £26 million ($33.1 million) Series B Follow-on Financing
January 30, 2024
Brighton, UK: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering